Eficacia de los fármacos antirreumáticos modificadores de la enfermedad sintéticos en artritis psoriásica: una revisión sistemática

Ceponis, 2010, Use of methotrexate in patients with psoriatic arthritis, Clin Exp Rheumatol., 28, S132 Ash, 2012, A systematic literature review of drug therapies for the treatment of psoriatic arthritis: Current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis, Ann Rheum Dis., 71, 319, 10.1136/ard.2011.150995 Pereda, 2012, Evidence-Based Working Group of the Spanish Society of Rheumatology. Efficacy and safety of DMARDs in psoriatic arthritis: A systematic review, Clin Exp Rheumatol., 30, 282 Ravindran, 2008, A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis, Ann Rheum Dis., 67, 855, 10.1136/ard.2007.072652 Acosta Felquer, 2014, Drug therapies for peripheral joint disease in psoriatic arthritis: A systematic review, J Rheumatol, 41, 2277, 10.3899/jrheum.140876 Gossec, 2012, European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies, Ann Rheum Dis., 71, 4, 10.1136/annrheumdis-2011-200350 Ritchlin, 2009, Treatment recommendations for psoriatic arthritis, Ann Rheum Dis., 68, 1387, 10.1136/ard.2008.094946 Huynh, 2015, 54, 20 Gottlieb, 2008, Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics, J Am Acad Dermatol., 58, 851, 10.1016/j.jaad.2008.02.040 Luelmo, 2014, A report of 4 years of experience of a multidisciplinary unit of psoriasis and psoriatic arthritis, Reumatol Clin., 10, 141, 10.1016/j.reuma.2014.01.004 Mease, 2013, Methotrexate in psoriatic arthritis, Bull Hosp Jt Dis, 71, S41 Sociedad Española Reumatología. Grupo de trabajo ESPOGUIA. Guía de Práctica Clínica para el Tratamiento de la Espondiloartritis Axial y la Artritis Psoriásica [monografía en Internet]. Madrid: Sociedad Española de Reumatología, 2015, Madrid [consultado Mayo 2016]. Disponible en: http://www.ser.es/wp-content/uploads/2016/01/GPC_Tratamiento_EspAax_APs_Espoguia2015.pdf Scottish Intercollegiate Guidelines Network (SIGN). Methodology checklist 1: Systematic reviews and metaanalyses [actualizado 06 Mayo 2014] [consultado Ene 2015]. Disponible en: http://www.sign.ac.uk/methodology/checklists.html Centre for Evidence Based Medicine (CEBM). Levels of evidence [consultado Dic 2014]. Disponible en: http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/ Kingsley, 2012, 51, 1368 Scarpa, 2008, The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: Results of a pilot randomised 6-month trial with methotrexate, Clin Rheumatol., 27, 823, 10.1007/s10067-007-0787-7 Asaduzzaman, 2014, Efficacy and safety of leflunomide in psoriatic arthritis, J Pakistan Assoc Dermatol, 24, 51 Asiri, 2014, The effectiveness of leflunomide in psoriatic arthritis, Clin Exp Rheumatol., 32, 728 Behrens, 2013, Leflunomide in psoriatic arthritis: Results from a large European prospective observational study, Arthritis Care Res., 65, 464, 10.1002/acr.21848 Chandran, 2008, Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: Results from a longitudinal observational cohort, J Rheumatol., 35, 469 Sociedad Española de Reumatología. Grupo de trabajo ESPOGUIA. Guía de Práctica Clínica sobre el manejo de los pacientes con Espondiloartritis 2009 [monografía en Internet] [consultado Dic 2014]. Madrid: Sociedad Española de Reumatología; 2010. Disponible en: Disponible en: http://www.ser.es/wp-content/uploads/2016/03/Espogu%C3%ADa-completa_1_def-1.pdf Helliwell, 2008, Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs —comparison of drugs and adverse reactions, J Rheumatol, 35, 472 Soriano, 2012, The actual role of therapy with traditional disease-modifying antirheumatic drugs in psoriatic arthritis, J Rheumatol Suppl., 89, 67, 10.3899/jrheum.120248 Coates, 2015, Outcome measures in psoriatic arthritis, Rheum Dis Clin North Am., 41, 699, 10.1016/j.rdc.2015.07.009 Möller, 2009, Efficacy of leflunomide in patients with psoriatic arthritis, Semin Fund Esp Reumatol., 10, 48 Sevrain, 2014, Treatment (biotherapy excluded) of psoriatic arthritis: An appraisal of methodological quality of international guidelines, J Eur Acad Dermatol Venereol, 28, 33, 10.1111/jdv.12564 Pincus, 2015, Clin Exp Rheumatol., 33, S82 Ramírez, 2016, Metrotexato en el tratamiento de la artritis psoriásica, Reumatol Clin Supl., 11, 36 Mease, 2012, Spondyloarthritis. Is methotrexate effective in psoriatic arthritis?, Nat Rev Rheumatol., 8, 251, 10.1038/nrrheum.2012.56 Altman, 1995, Absence of evidence is not evidence of absence, BMJ., 311, 485, 10.1136/bmj.311.7003.485 Coates, 2011, Development of a disease severity and responder index for Psoriatic Arthritis (PsA) —Report of the OMERACT 10 PsA special interest group, J Rheumatol, 38, 1496, 10.3899/jrheum.110278